SubsidieMeestersThe ProM platform: New ways to drug the undruggable
PROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer.
Projectdetails
Introduction
Existing pharmaceutical methods can only target 15% of all proteins in the human proteome. Given this limitation, pharmaceutical companies are running out of options to develop effective drugs to tackle hard-to-treat diseases. To have a better chance of fighting these diseases, further targets of the remaining, so far undruggable 85% of our proteome need to be unlocked.
PROSION's Innovative Solution
PROSION developed a disruptive platform of chemical building blocks called ProMs. The ProM-platform addresses a specific class of yet undruggable proteins linked to hard-to-treat diseases.
Applications of ProMs
ProMs can be combined into small molecule drugs to target proteins that play a key role in pathologies such as:
- Cancer
- Alzheimer’s
- Cardiovascular diseases
- Immune-mediated disorders
Current Validation Efforts
The platform’s potential is currently being validated. In its first project, PROSION addresses a yet undruggable target to potentially provide new therapies for pancreatic and breast cancer and fight drug-resistance effects within cancer therapies.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.461.375 |
| Totale projectbegroting | € 3.516.250 |
Tijdlijn
| Startdatum | 1-4-2022 |
| Einddatum | 31-3-2025 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- PROSION GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPYMYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes. | EIC Accelerator | € 2.494.504 | 2023 | Details |
FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY
MYCureX aims to evaluate the safety and efficacy of OMO-103, a novel MYC inhibitor, in combination with standard care for PDAC, while refining companion diagnostics for improved patient outcomes.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Protease Profiling and Triggered Drug Delivery for Personalized Cancer TherapyPROTECT aims to develop a novel platform using Liposomal Activity-Based Sensors for sensitive protease profiling to enhance cancer diagnostics and personalized drug delivery. | ERC Consolid... | € 1.842.642 | 2022 | Details |
Inhibitor-Mediated Programming of GlycoformsThe project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions. | EIC Pathfinder | € 2.998.878 | 2025 | Details |
Deciphering regulatory principles of proteasome heterogeneity and the degradation landscape in cancerThe project aims to enhance understanding of proteasome activity in cancer through MAPP technology, exploring its role in tumor-immune interactions and potential for improving immunotherapy outcomes. | ERC Consolid... | € 1.978.750 | 2022 | Details |
Preclinical in vivo proof-of-concept for cyclic oligopeptide rescuers of pathogenic protein misfolding and aggregation associated with neurodegenerationThe PoC4ProMis project aims to demonstrate in vivo efficacy of novel cyclic peptides for ALS using optimized CNS delivery methods, while strengthening IP for potential neurodegenerative disease treatments. | ERC Proof of... | € 150.000 | 2024 | Details |
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approachTrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space. | ERC Starting... | € 1.499.625 | 2022 | Details |
Protease Profiling and Triggered Drug Delivery for Personalized Cancer Therapy
PROTECT aims to develop a novel platform using Liposomal Activity-Based Sensors for sensitive protease profiling to enhance cancer diagnostics and personalized drug delivery.
Inhibitor-Mediated Programming of Glycoforms
The project aims to revolutionize glycan manipulation using Inhibitor-Mediated Programming of Glycoforms (IMProGlyco) to create precision-engineered therapeutic proteins and enhance cellular functions.
Deciphering regulatory principles of proteasome heterogeneity and the degradation landscape in cancer
The project aims to enhance understanding of proteasome activity in cancer through MAPP technology, exploring its role in tumor-immune interactions and potential for improving immunotherapy outcomes.
Preclinical in vivo proof-of-concept for cyclic oligopeptide rescuers of pathogenic protein misfolding and aggregation associated with neurodegeneration
The PoC4ProMis project aims to demonstrate in vivo efficacy of novel cyclic peptides for ALS using optimized CNS delivery methods, while strengthening IP for potential neurodegenerative disease treatments.
Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach
TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.